Sotrovimab for COVID-19: real-time analysis of all 1 studies

Download Image


5/26	Early	GlaxoSmithKline (Preprint)	death, ↓66.6%, p=1.00	Sotrovimab Clinical, Safety, & Variant Information
	Details Interim results from the COMET-ICE trial showing lower mortality and progression with treatment. NCT04545060.
5/26	Details Source PDF Early treatment study Early treatment study
	GlaxoSmithKline (Preprint)
	Sotrovimab Clinical, Safety, & Variant Information
	Interim results from the COMET-ICE trial showing lower mortality and progression with treatment. NCT04545060. risk of death, 66.6% lower, RR 0.33, p = 1.00, treatment 0 of 291 (0.0%), control 1 of 292 (0.3%), continuity correction due to zero event. risk of disease progression, 85.0% lower, RR 0.15, p = 0.002, treatment 3 of 291 (1.0%), control 21 of 292 (7.2%), adjusted. GlaxoSmithKline et al., 5/26/2021, Double Blind Randomized Controlled Trial, USA, North America, preprint, 1 author.
	Share Tweet Submit Corrections or Comments

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit